Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
mesothelioma/albumiin
Link salvestatakse lõikelauale
Leht 1 alates 57 tulemused
The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional Study.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
Malignant pleural mesothelioma (MPM), a devastating neoplasm, is traditionally considered to be resistant to antitumor therapy. Identification of clinical prognostic indicators is therefore needed. Although the C-reactive protein/albumin ratio (CAR) has been used to predict the prognosis
Repetitive responses to nanoparticle albumin-bound paclitaxel and carboplatin in malignant pleural mesothelioma.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Malignant pleural mesothelioma (MPM) is a rare tumor with a poor prognosis. Although cisplatin plus pemetrexed is the standard chemotherapy for patients with unresectable MPM, few agents are available for MPM patients who do not tolerate pemetrexed. Here, we report the first case of an MPM patient
Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Our aim was to evaluate the prognostic role of the pretreatment serum albumin level in patients with malignant pleural mesothelioma (MPM) receiving platinum-based systemic chemotherapy. From 1995 to 2013, a total of 97 patients receiving platinum-based systemic chemotherapy for newly diagnosed MPM
ASO Author Reflections: C-Reactive Protein/Albumin Ratio as a Prognostic Factor in Patients with Malignant Pleural Mesothelioma: What Does the Novel Index Represent?
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The C-Reactive Protein/Albumin Ratio May Predict the Long-Term Outcome in Patients with Malignant Pleural Mesothelioma.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Development of a biosensor for detection of pleural mesothelioma cancer biomarker using surface imprinting.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Hyaluronan-linked protein 1 (HAPLN1) which has been shown to be highly expressed in malignant pleural mesotheliomas (MPM), was detected in serum using an electrochemical surface-imprinting method. First, the detection method was optimized using Bovine serum albumin (BSA) as a model protein to mimic
Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Methotrexate-albumin conjugate (MTX-HSA) is a novel human albumin-based prodrug conjugate of methotrexate (MTX). A low MTX loading rate provided optimal tumor targeting and therapeutic efficacy during preclinical testing. The objectives of this first Phase I study of MTX-HSA were to determine
Prediction modelling using routine clinical parameters to stratify survival in Malignant Pleural Mesothelioma patients undergoing cytoreductive surgery.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
Malignant Pleural Mesothelioma (MPM) is an uncommon cancer with a poor prognosis and heterogeneous survival. Surgery for MPM is offered in some specialist centres to highly selected patients. A previously described classification and regression tree (CART) model stratified survival in
A multifunctional mesothelin antibody-tagged microparticle targets human mesotheliomas.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Pleural and peritoneal mesotheliomas (MMs) are chemoresistant tumors with no effective therapeutic strategies. The authors first injected multifunctional, acid-prepared mesoporous spheres (APMS), microparticles functionalized with tetraethylene glycol oligomers, intraperitoneally into rodents.
Analysis of prognostic factors of patients with malignant peritoneal mesothelioma.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
The study aims to find out independent prognostic factors for patients with malignant peritoneal mesothelioma (MPeM).
METHODS
Patients with pathologically proven MPeM were retrospectively reviewed. Potential prognostic factors were analyzed, including age, gender, asbestos exposure, body
Survival from malignant mesothelioma: where are we now?
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
The prognosis of malignant pleural mesothelioma has traditionally been poor. Whether this remains the case compared to historical data and within a specific geographical location is uncertain. Knowledge of predictive factors for survival with malignant pleural mesothelioma is also
Predictive factors analysis for malignant peritoneal mesothelioma.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
Malignant peritoneal mesothelioma (MPM) is an uncommon disease with a dismal prognosis and unclear natural history. The present study aims to assess potential prognostic factors and management of MPM.
METHODS
Clinical records of 39 patients with MPM between December 2003 and April 2014
EphB4 as a therapeutic target in mesothelioma.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
Malignant pleural mesothelioma (MPM) often develops decades following exposure to asbestos. Current best therapy produces a response in only half of patients, and the median survival with this therapy remains under a year. A search for novel targets and therapeutics is underway, and
[Malignant peritoneal mesothelioma].
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The peritoneal mesothelioma is a rare pathology with unspecific symptoms reason to be a difficult diagnosis. We report a case of a 58 year old man with diabetes mellitus type 2, arterial hypertension and smoking; without precedent of asbestos exposure. The patient presented a one month history
Minimal change disease associated with malignant pleural mesothelioma: case report and review of the literature.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
A 77-year-old man with a history of asbestos exposure was admitted to our internal medicine division for generalised weakness, fatigue, loss of weight, night sweats and difficulty for breathing since 3 months. Clinical examination revealed left fine crackles and bilateral leg oedema. Blood test
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
